Cariboni U, et al. - Via this retrospective review of 154 sarcoma patients who underwent pulmonary metastasectomy (PM) from 1997 to 2015 at Humanitas Cancer Center, researchers investigated the clinical outcome of PM, as well as prognostic factors linked with local control, disease-free, and overall survival (OS) in sarcoma patients by using a univariable and multivariable Cox regression analysis. Analysis of clinicopathologic, surgical, and survival data was carried out and cases with a follow-up period less than 1 year were excluded. After a median follow-up of 24 months, the median OS from initial metastasectomy was 35.4 months. Based on OS, three histology risk groups were defined: high risk (myxofibrosarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma), intermediate risk (leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma), and low risk (synovial and chondrosarcoma). For these risk groups, the estimated 3-year OS was 21.4%, 45.7%, and 74.1%, respectively. PM was supported as a valid option to treat sarcoma. Independent negative prognostic factors identified in this study included high-risk histologies and bilaterality of lung metastases. Patient selection could be improved via a prognostic score.